Cartesian Therapeutics Reports Presentation Of Data From Its Phase 2b Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis;
Cartesian Therapeutics Reports Presentation Of Data From Its Phase 2b Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis;
Cartesian Therapeutics宣佈在普遍性重症肌無力患者中進行第20億階段Descartes-08試驗數據報告;
- The trial achieved its primary endpoint with statistical significance in the pre-specified modified intent-to-treat efficacy population, with 71% (10/14) of patients treated with Descartes-08 observed to have 5-point or greater improvements in MG Composite (MGC) score at Month 3 compared to 25% (3/12) of patients treated with placebo (p=0.018).
- 該試驗在預定修正意圖治療有效人群中以統計學顯著性實現了其主要終點，觀察到接受 Descartes-08 治療的患者中有71%（10/14）在第3個月時MG綜合評分（MGC）有5分或更高的改善，而接受安慰劑治療的患者中有25%（3/12）（p=0.018）。
Carsten Brunn, Ph.D., President and Chief Executive Officer, said, "We look forward to continuing to collaborate with the FDA to determine next steps for the Descartes-08 program for MG and plan to hold an End-of-Phase 2 meeting by the end of this year."
卡斯滕·布倫（Carsten Brunn）博士，總裁兼首席執行官表示：「我們期待繼續與FDA合作，以判斷 Descartes-08 計劃在MG領域的下一步計劃，並計劃於今年年底舉行第2階段結束會議。」
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間